Ozempic deficiency ended

US food and drug control Defined this Semglutide It’s not over shortageA movement that will affect patients receiving cheaper, complex versions of the drug.

Semaglutide, active ingredient Novo Nordisk’s Blockbuster Diabetes and weight loss drugs Ozempic and Wegovytook place Fda This shortcoming list since March 2022. Supply pace could not continue Demand for the drugNovo reached the level of popularity reaching such dizzying levels that converted Nordisk into one of the most valuable companies in the world Market capitalization The Danish house is greater than the rest of the economy.

In the years of intervention, an income industry Telesetrich companies, medical spa and pharmacies Making and selling “complex” copies The drugs have been created. These off-branded copies may have more than $ 1000 per month in a steep discount, which can exceed $ 1000 per month, which may be more than $ 1,000 per month.

At the end of October, Fda, Ozempic and Wegovy changed the situation of all the doses of the doses of “existence” that was likely to see the end of the official deficit. So far, about four months later, the regulators were quite possible to be quite wide to remove the drug’s lack of drugs.

Fda gives “503A” inks are usually a state licensed pharmacy or smaller operations to stop the production of doctors or doctors. Until May 22, the inks of “503B”, which are larger external devices that follow the rules of harder production.

In ordinary cases, the drugs are not particularly controversial when they get out of the shortcoming list. However, there is a reason to believe that the players in this industry will give this announcement.

Drug combination is a well-established experience; Pharmacists are allowed to make copies of drugs when there is a lack of medicine or when patients need versions without special doses or allergens. However, the complex that changed the GLP-1 BOOM, industrial pockets, probably created an opportunity for the pharmacies that produce brand duplicates for millions of patients.

Robert MacArthur, Rochefeller University Hospital Robert Macarthur, after leaving a drug shortfall list, the outsourcing pharmacies that make large explosions for health facilities, no more involved in the drug. But this is a legally gray region for small, traditional combinative pharmacies that take medication for home use.

“Doctor writes the recipe for an individual patient, and if the patient feels a special complex product,” MacArthur “says. This reason can adjust the dose or adapt to a certain patient.

Some Telehealth said they intended to continue offering their products. , founder and its executive director and health, write In X, it adds that the company’s potential future deficiencies are closely monitored.